Two-month treatment of obese subjects with the oral growth hormone secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure
Svensson J, Lönn L, Jansson JO, et al.
Journal of Clinical Endocrinology & Metabolism, 1998 · n = 24
Key finding
MK-677 increased fat-free mass and energy expenditure in obese subjects but simultaneously raised fasting glucose, highlighting the metabolic trade-off.
Summary
Two-month trial in obese subjects showing MK-677 increased GH secretion, fat-free mass by 3 kg, and basal metabolic rate, while fasting glucose also increased.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on MK-677
Growth hormone secretagogues as potential therapeutic agents to restore growth hormone secretion in older subjects
Journals of Gerontology: Series A · 2023 · Review
MK-677 and Alzheimer's disease: neuroprotection and cognitive decline in animal models
Journal of Alzheimer's Disease · 2012 · Animal Study
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial
Annals of Internal Medicine · 2008 · Human RCT
MK-677 and cognitive function in aged subjects: memory and executive function
European Journal of Endocrinology · 2008 · Human Pilot
MK-677 in cachexia and wasting diseases: preclinical efficacy studies
Nutrition & Metabolism · 2008 · Animal Study